FDA PDUFA review goal date of March 27, 2025 for CARDAMYSTâ„¢ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)Assuming ...
Milestone Pharmaceuticals Inc. announced that the FDA has set a PDUFA review goal date of March 27, 2025, for its nasal spray CARDAMYSTâ„¢ (etripamil), aimed at treating Paroxysmal ...
on a new Method of Use patent for etripamil nasal spray, with proposed trade name CARDAMYST, its lead investigational product for the management of paroxysmal supraventricular tachycardia ...
The study will use the patient self-administration 70-mg repeat-dose regimen, of etripamil nasal spray, outside of the medically supervised setting, similar to that used in the PSVT development ...
The study will use the patient self-administration 70-mg repeat-dose regimen, of etripamil nasal spray, outside of the medically supervised setting, similar to that used in the PSVT development ...
Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and ...
Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and ...
The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...
The CARDAMYST brand name is conditionally approved by the FDA. Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for ...